Novo Nordisk stock news
On May 7, 2026, Novo Nordisk announced its participation in the "Medicare GLP--1 Bridge" program, a Centers for Medicare & Medicaid Services (CMS) initiative set to commence on July 1, 2026. The program will grant eligible Medicare beneficiaries living with obesity access to both Wegovy (semaglutide) injections and the newly launched Wegovy tablets for a $50 monthly copay. This expansion is expected to significantly increase patient volume within the U.S. senior population, leveraging Wegovy's unique FDA--approved indication for reducing major cardiovascular risks in patients with heart disease and obesity.